FOR IMMEDIATE RELEASE September 24, 2018 Trulieve Achieves Significant Growth in the Second Quarter of 2018 Quincy, Florida - Trulieve Cannabis Corp. (CSE: TRUL) (“Trulieve” or the “Company”) today announces its financial results for the three and six-month periods ended June 30, 2018.
The Company’s second quarter 2018 financial statements have been filed as part of its listing statement with the Canadian Securities Exchange (“CSE”). This news release is not in any way a substitute for reading those financial statements, including the notes to the financial statements. Unless otherwise stated, all currency is expressed in U.S. dollars.
Q2 2018 Highlights -
16 dispensaries in operation
83,000 active unique patients
Revenue grew from $15.2 million in Q1 2018 to $23.3 million in Q2 2018
EBITDA increased from $11.2 million in Q1 2018 to $14.3 million in Q2 2018
“The second quarter of 2018 demonstrated our ability to scale our business profitably with growth in dispensaries and patients served driving growth in revenue and EBITDA ,” said Kim Rivers, CEO of Trulieve. “This momentum is continuing in the current quarter and we expect strong results throughout 2018.”
Results of Operations (millions of U.S. dollars) 2017 2018 Q1 % change 2018 Q2 Total Revenue 19.8 15.2 53.3 23.3 Gross Margin2 8.7 10.7 61.7 17.3 Gross Margin % 43.9 69.3 6.9 74.1 Operating Expenses 8.3 4.6 30.4 6.0 Operating Expenses % 42.0 30.1 (14.3) 25.8 EBITDA1 10.1 11.2 27.7 14.3 1.
Contact: Kevin Darmody, Director of Investor Relations (850) 480-7955 IR@Trulieve.com 6749 Ben Bostic Road, Quincy, Florida 32351 http://www.trulieve.com
About Trulieve Trulieve is a vertically integrated “seed to sale” company and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery.
Issued & Outstanding: 11,127,500